Your browser doesn't support javascript.
loading
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
Waks, A G; Cohen, O; Kochupurakkal, B; Kim, D; Dunn, C E; Buendia Buendia, J; Wander, S; Helvie, K; Lloyd, M R; Marini, L; Hughes, M E; Freeman, S S; Ivy, S P; Geradts, J; Isakoff, S; LoRusso, P; Adalsteinsson, V A; Tolaney, S M; Matulonis, U; Krop, I E; D'Andrea, A D; Winer, E P; Lin, N U; Shapiro, G I; Wagle, N.
Afiliação
  • Waks AG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Department of Medicine, Brigham and Women's Hospital, Boston, USA; Broad Institute of MIT and Harvard, Cambridge, USA; Harvard Medical School, Boston, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, B
  • Cohen O; Broad Institute of MIT and Harvard, Cambridge, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, USA.
  • Kochupurakkal B; Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, USA.
  • Kim D; Broad Institute of MIT and Harvard, Cambridge, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, USA.
  • Dunn CE; Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, USA.
  • Buendia Buendia J; Broad Institute of MIT and Harvard, Cambridge, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, USA.
  • Wander S; Broad Institute of MIT and Harvard, Cambridge, USA; Harvard Medical School, Boston, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, USA; Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, USA.
  • Helvie K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, USA.
  • Lloyd MR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; University of Massachusetts Medical School, Worcester, USA.
  • Marini L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, USA.
  • Hughes ME; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.
  • Freeman SS; Broad Institute of MIT and Harvard, Cambridge, USA.
  • Ivy SP; Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, USA.
  • Geradts J; City of Hope Comprehensive Cancer Center, Duarte, USA.
  • Isakoff S; Harvard Medical School, Boston, USA; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, USA.
  • LoRusso P; Yale Cancer Center, New Haven, USA.
  • Adalsteinsson VA; Broad Institute of MIT and Harvard, Cambridge, USA.
  • Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Department of Medicine, Brigham and Women's Hospital, Boston, USA; Harvard Medical School, Boston, USA.
  • Matulonis U; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Department of Medicine, Brigham and Women's Hospital, Boston, USA; Harvard Medical School, Boston, USA.
  • Krop IE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Department of Medicine, Brigham and Women's Hospital, Boston, USA; Harvard Medical School, Boston, USA.
  • D'Andrea AD; Harvard Medical School, Boston, USA; Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, USA; Department of Radiation Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA.
  • Winer EP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Department of Medicine, Brigham and Women's Hospital, Boston, USA; Harvard Medical School, Boston, USA.
  • Lin NU; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Department of Medicine, Brigham and Women's Hospital, Boston, USA; Harvard Medical School, Boston, USA.
  • Shapiro GI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Department of Medicine, Brigham and Women's Hospital, Boston, USA; Harvard Medical School, Boston, USA; Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, USA.
  • Wagle N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Department of Medicine, Brigham and Women's Hospital, Boston, USA; Broad Institute of MIT and Harvard, Cambridge, USA; Harvard Medical School, Boston, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, B
Ann Oncol ; 31(5): 590-598, 2020 05.
Article em En | MEDLINE | ID: mdl-32245699
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Neoplasias da Mama Limite: Female / Humans Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Neoplasias da Mama Limite: Female / Humans Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article